FBFrédéric de Blay

Frédéric de Blay

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frédéric de Blay has a total of 761 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps

    by Angelica Tiotiu, Nicolas Migueres, Francisco-Javier Gonzalez-Barcala, Pauline Roux, Jean-Philippe Oster, Natacha Moutard, Frederic de Blay, Philippe Bonniaud


  • Open Access

    Rhinoconjunctivitis severity induced by cat exposure influences early and late asthmatic responses: Evidence from an environmental exposure chamber

    by Anays Piotin, Julien Godet, Nathalie Domis, Frédéric de Blay

    Background: The impact of allergic rhinoconjunctivitis on the early (EAR) and late asthmatic response (LAR) has yet to be assessed during optimal allergen exposure conditions.Objective: We aimed to assess predictive factors of the EAR and LAR and to evaluate the relation between rhinitis, conjunctivitis and asthma induced by cat allergen exposure in an environmental exposure chamber (EEC).Methods: Data from two cohort studies involving asthmatic patients with cat allergy who performed a cat allergen exposure challenge in ALYATEC EEC were analysed. Spirometry, visual analogue scale (VAS) for asthma, VAS for rhinitis, Total Nasal Symptoms Score, Total Ocular Symptoms Score (TOSS), Rhinoconjunctivitis Total Symptoms Score and Abelson score were used to assess asthma, rhinitis and conjunctivitis during and after exposure.Results: An EAR occurred in 65.1% of patients, 32.1% of whom had a LAR. The diameter of the prick test to cat allergens and non‐specific bronchial hypersensitivity level were independent risk factors for EAR (p < .05). No independent risk factors for LAR were identified. Rhinoconjunctivitis severity during exposure correlated with the asthma VAS during EAR and LAR (p < .05). Allergen exposure time needed to trigger an EAR correlated with the Abelson score during exposure (p < .05). The asthma VAS and TOSS during exposure correlated with faster LAR occurrence (p < .05).Conclusion: Prick test size and non‐specific bronchial hypersensitivity level were confirmed as independent predictive factors of EAR during allergen exposure in an EEC. This study demonstrated the relation between the severity of rhinitis, conjunctivitis and asthma induced by allergen exposure for both EAR and LAR.


  • Open Access

    Birch allergen challenges in allergic conjunctivitis using unitary tests and an exposure chamber

    by Alina Gherasim, Jean Luc Fauquert, Nathalie Domis, Xavier Siomboing, Nicole Beck, Tristan Bourcier, Frédéric De Blay

    Background: Environmental exposure chambers (EECs) have been used extensively to study allergic rhinoconjunctivitis. Few studies have been published using EECs in conjunctivitis only, and none have used conjunctival allergen challenge as a selection criterion. The present study validated ALYATEC EEC in allergic conjunctivitis to birch allergens. Methods: Sixteen patients with a positive conjunctival allergen challenge (CAC) were ex-posed to 60 ng/m3 of Bet v 1 in an EEC on 2 consecutive days for a maximum of 4 hours. Re-producibility was tested among seven of the patients. A positive conjunctival response during the CAC and the EEC exposure was defined as a Total Ocular Symptom Score (TOSS) ≥ 5. Results: Fifty percent of patients had a positive conjunctival response during the first expo-sure and 75% during the second. The mean time to a positive conjunctival response was 81.2±33.9 minutes and 101.6±57 (P>0.05) during the first and second exposure, respectively. No difference in the TOSS occurred between the two exposures. The time necessary to ob-tain a positive response during the CAC was significantly shorter than with the EEC. The es-timated quantity of Bet v 1 inducing a positive response was 0.07±0.03 ng (exposure 1), 0.07±0.07 ng (exposure 2), 980±784 ng (CAC). The frequency of conjunctival responses and quantity of Bet v 1 was reproducible in all six EEC exposures. Conclusions: Birch allergen exposures inducing early conjunctival responses were different than those identified with direct installation during CAC. EEC appears to be closer to natural exposure than CAC.

  • Human platelets do not possess the FcεRI and FcεRII receptors for IgE

    by Charles Tacquard, Florian Tupin, Stéphanie Magnenat, Nathalie Brouard, Anita Eckly, Fabienne Proamer, Carine Metz‐Favre, Rodolphe Stenger, Anays Piotin, Frédéric De Blay, et al.


  • Top Cited Papers
    Open Access

    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

    by J. Bousquet, E. Melén, T. Haahtela, G. H. Koppelman, A. Togias, R. Valenta, C. A. Akdis, W. Czarlewski, M. Rothenberg, A. Valiulis, et al.

    Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.


  • Open Access

    Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

    by Bernardo Sousa-Pinto, Cristina Jácome, Ana Margarida Pereira, Frederico S Regateiro, Rute Almeida, Wienczyslawa Czarlewski, Marek Kulus, Mohamed H Shamji, Louis-Philippe Boulet, Matteo Bonini, et al.


  • Induction of immunosuppressive CD39 but not the trafficking C‐C chemokine receptor 4 on Treg during LAR in mite allergic asthma

    by Virginie Doyen, Anh Poirot, Myriam Maumy‐Bertrand, Frederic Bertrand, Naji Khayath, Nathalie Domis, Frederic de Blay

  • Open Access

    Laryngeal dysfunction is prominent in asthmatic women treated by inhaled corticosteroids

    by Nicolas Migueres, Christina Delmas, Julie Petit Thomas, Hélène Kuntz, Elisabeth Peri‐Fontaa, Philippe Schultz, Michel Velten, Frédéric de Blay

    Background: Dysphonia is a frequent comorbidity of asthma and has been suggested to be a local side effect of inhaled corticosteroids due to laryngeal candidiasis. We hypothesized that dysphonia in asthmatics was not due to laryngeal organic lesions but to laryngeal dysfunction during phonation (LDP).Objective: We compared the frequency of LDP in female asthmatic patients treated with inhaled corticosteroids to female controls.Methods: We compared 68 asthmatic female patients to 53 female control subjects. Pulmonary function tests were performed and the asthmatic patients classified according to the level of inhaled corticosteroids. Dysphonia was defined as a Vocal Handicap Index ≥18 or GRBAS score ≥2. All patients underwent video laryngo‐strobe examination, analyzed blindly and separately by two otolaryngologists, describing mucosal changes, LDP, or Organic lesions linked to Laryngeal Dysfunction during Phonation (OLDP).Results: 66.2% of the asthmatic patients exhibited dysphonia and 11.3% of controls (p < 0.001). No laryngeal candidiasis was found, only 3 patients presented laryngeal mucosa inflammation. LDP was observed in 60.3% of asthmatic patients and 18.9% of controls (p < 0.001), and no difference was found for OLDP (11.8% vs. 13.2%). No association was made between LDP, the dosage of inhaled corticosteroid, and bronchial obstruction.Conclusions: Asthmatic patients were more dysphonic than control subjects. This phenomenon was not explained by mucosal inflammation, laryngeal candidiasis or OLDP. Asthmatic patients had more LDP than controls. There was no relation between LDP, inhaled corticosteroids dosage or bronchial obstruction. These results change our view of inhaled corticosteroid side effects in female asthmatic patients.


  • Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations

    by Lise Melscoet, Naji Khayath, Nicolas Migueres, Marc-André Goltzene, Nicolas Meyer, Frédéric de Blay

    Introduction: Humanized monoclonal anti-IgE antibody (omalizumab) has demonstrated efficacy in severe atopic asthma. However, few studies have assessed its efficacy in non-atopic and even less in T2-low severe asthma. The objective was to determinate the omalizumab response according to atopic status. Methods: This retrospective, real-world study was performed in the Chest Diseases Department of Strasbourg University Hospital from January 1, 2006, to June 30, 2017. The response to omalizumab was assessed in 139 patients 4, 6, and 12 months after treatment and compared to data collected prior to omalizumab initiation. Results: Forty-four patients (31.7%) had severe non-atopic asthma and 95 (68.3%) had a severe atopic asthma. In the non-atopic group, omalizumab significantly reduced the severe exacerbation rate by 44% (95% CI 18-64%, p < 0.05), 43% (CI 95% 20-60%, p < 0.05), and 54% (CI 95% 36-67%, p < 0.05), at 4, 6 and 12 months, respectively. A trend toward improvement in FEV1, asthma control and oral corticosteroid use was also observed. These results were not significantly different from those obtained in atopic asthmatics except a more effective oral corticosteroid sparing in atopic group (p < 0.05). Similar reduction of severe exacerbation rates were observed in T2-low asthma subgroup (non-atopic, non-eosinophilic). Conclusion: Omalizumab was effective in severe asthma, regardless of atopic status.


  • Open Access

    Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma

    by Nicolas Migueres, Anh Poirot, Nan Zhang, Claus Bachert, Frédéric De Blay

    Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma Nicolas Migueres1,2, Anh Poirot1, Nan Zhang ,3,4, Claus Bachert 3,4, Frédéric de Blay1 ,51: Chest Diseases Department, Strasbourg University Hospital, Strasbourg France.2: UMR 7357 Laboratoire des sciences de l’ingénieur, de l’informatique et de l’imagerie ICUBE3: Upper Airways Research Laboratory, Ghent University, Ghent, Belgium4: Division of ENT diseases, CLINTEC, Karolinska Institute, University of Stockholm, Sweden5: EA 3072, Fédération de médecine translationnelle, université de Strasbourg, 67000 Strasbourg, FranceCorresponding author: Nicolas Migueres, nicolas.migueres@chru-strasbourg.frChest Diseases DepartmentNouvel Hôpital CivilHopitaux Universitaires de Strasbourg67093 STRASBOURG CEDEXtel: 00 33 6 07 60 51 86,Total word count ( 570 words)Author Contributions: All investigators contributed to the conception and design of the study. All authors contributed to the acquisition, analysis and interpretation of the data. They provided input into the drafting of the manuscript, critical feedback, and final approval for submission of the manuscript for publication. NM is the guarantor of the final content of the manuscript.The authors have no conflicts of interest to declare.